Apalutamide Active in Castration - Resistant Prostate Cancer

Apalutamide prolongs metastasis - free survival in non - metastatic castration - resistant prostate cancer
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pharmacy, Urology, Conference News, Source Type: news

Related Links:

ConclusionsPRTB is only used in a minority of patients dying of PCa. The majority who die of PCa after PRTB do so within a year of their first course. The use of multifractionation was common in the last 4 weeks of life. Survival after first PRTB increased minimally over time, and additional research is required to identify its association with recent changes in practice. The referral rate and PRTB utilization rate differ between rural and nonrural locations, underlying the importance of accessibility and referral for utilization of PRTB. Investigating other barriers and ensuring equitable access to radiation are needed.
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 21 February 2019Source: Life SciencesAuthor(s): Changhwan Yeo, Hyo-Jeong Lee, Eun-Ok LeeAbstractAimsSerum is widely used for in vitro cell culture of eukaryotic cells. Although serum is well known to affect various biological activities in cancer cells, its effect in vasculogenic mimicry (VM) is not yet fully defined. Thus, this study investigated the role of serum in VM in human prostate cancer (PCa) PC-3 cells.Main methodsInvasion assay and 3D culture VM tube formation assay are performed. VM-related molecules are checked by western blot and reverse transcriptase-polymerase chain reacti...
Source: Life Sciences - Category: Biology Source Type: research
ConclusionsEPIC-CP was generally endorsed by clinicians and patients. The implementation of a disease-specific measure in place of a generic symptom screening tool has the potential to improve the quality of the clinical encounter and provide outcome measures for further health services research. Provincial implementation of this tool as a standard of care is recommended.
Source: Quality of Life Research - Category: Health Management Source Type: research
AbstractPurposeThe purpose of the study was to compare completeness, timeliness and cost of patient-reported outcome measures (PROMs) collection using telephone, email and post in men with prostate cancer.MethodsA parallel, three-arm randomised controlled equivalence trial. 1168 patients were randomised to telephone (n = 295), postal (n = 388) and email (n = 385) arms. Participants were asked to provide self-reported responses for 26 items of Expanded Prostate Cancer Index Composite. Cost and resource data were collected from a provider perspective.ResultsEquivalence tests showed n...
Source: Quality of Life Research - Category: Health Management Source Type: research
ConclusionsMen with mCRPC harboring ATM mutations experienced inferior outcomes to PARP inhibitor therapy compared to those harboring BRCA1/2 mutations. Alternative therapies should be explored for patients with ATM mutations.Patient summaryMutations in BRCA1/2 and ATM genes are common in metastatic prostate cancer. In this study we compared outcomes for men with BRCA1/2 mutations to those for men with ATM mutations being treated with olaparib. We found that men with ATM mutations do not respond as well as men with BRCA1/2 mutations.
Source: European Urology - Category: Urology & Nephrology Source Type: research
Data Presented at the 2019 Genitourinary Cancers Symposium Reinforces Benefits of Short Course of Treatment Using Stereotactic Body Radiation Therapy for Low- or Intermediate-Risk Prostate Cancer SUNNYVALE, Calif., Feb. 22, 2019 -- (Healthcare Sales &M... Devices, Oncology Accuray, stereotactic body radiation therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
The latest trial results are based on a larger patient population and were reported at the 2019 ASCO Genitourinary Cancers Symposium.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
ConclusionsRRP and RARP are associated with the same risk for the development of a SLC. Posterior approach does not reduce the SLC formation compared to the anterior technique. Patients ’ age and LN yield are predictive for the SLC occurrence in patients treated with RRP.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
This study applied a dual-agent, 13C-pyruvate and 13C-urea, hyperpolarized 13C magnetic resonance spectroscopic imaging (MRSI) and multi-parametric (mp) 1H magnetic resonance imaging (MRI) approach in the transgenic adenocarcinoma of mouse prostate (TRAMP) model to investigate changes in tumor perfusion and lactate metabolism during prostate cancer development, progression and metastases, and after lactate dehydrogenase-A (LDHA) knock-out. An increased Warburg effect, as measured by an elevated hyperpolarized (HP) Lactate/Pyruvate (Lac/Pyr) ratio, and associated Ldha expression and LDH activity were significantly higher in...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Condition:   Low Risk Prostate Cancer Intervention:   Drug: TOOKAD VTP Sponsors:   Steba Biotech S.A.;   International Drug Development Institute;   PrimeVigilance LTD Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Conferences | Prostate Cancer | Urology & Nephrology